Clinical trial NCT01556477: The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
Official title: A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Keywords: MDS
AML
Azacitidine
Lenalidomide
del5q
Lead sponsor: Nordic MDS Group
Sponsor class: NETWORK
First posted: 2012-03-16
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The proposed phase II trial is a multicenter, randomized, open-label study that will evaluate the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) with a karyotype including del(5q). The primary objective will be to evaluate the efficacy in terms of response according to International Working Group (IWG) criteria for MDS and AML after 6 cycles of azacitidine or azacitidine + lenalidomide treatment, or at end of study if this occurs at an earlier time point.

Detailed description: This is an prospective open multi-center randomized phase II study of standard dose azacytidine with or without the addition of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q). Seventy-two patients, eligible for treatment with azacytidine (Intermedium/INT-2 and High-risk MDS and AML with 20-30 % marrow blasts according to label) will be included.

Azacytidine will be given in a modified standard dose, azacytidine 5+2 (75 mg/m2/ d subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacytidine 75 mg/m2/ d for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles. Cycle interval may be prolonged if toxicity according to predefined criteria occurs. Patients will be randomized to azacytidine (Arm A) or azacytidine + lenalidomide (Arm B). The initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacytidine cycle and leaving the last week before start of next azacytidine cycle free. The dose should be increased to 20 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. The total study period is 24 weeks + additional weeks caused by prolonged cycle interval. Patients, who following a response may be eligible for allo-SCT may exit the study after cycle 3, 4 or 5 and then be subject to end-of-study assessment. Patients who at start of treatment, or any time during study have a neutrophil count \<0,5 x 109/l will be treated with Granulocyte-ColonyStimulatingFactor (G-CSF).

Eligibility criteria: Inclusion Criteria:

* 18 years of age at the time of signing the informed consent form.
* MDS with IPSS Int-2 or High with a karyotype including del(5q).
* Acute myeloid leukaemia (AML) with multilineage dysplasia and 20-30 % blasts (former RAEB-t) with a karyotype including del(5q).
* Subject has signed the informed consent form.
* Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test prior to starting lenalidomide. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, patches, or implantable hormonal contraceptive methods; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on lenalidomide. WCBP must agree to have pregnancy tests every 4 weeks while on lenalidomide.
* Males (including those who have had a vasectomy) must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with WCBP while on lenalidomide, when temporarily stopping lenalidomide and 28 days after the last dose of lenalidomide.

Note: Refractory and relapsed patients can be included as long as they fulfil the inclusion criteria.

Exclusion Criteria:

* Eligible for upfront allogeneic SCT without prior induction chemotherapy or azacitidine
* Pregnant or lactating females.
* Prior therapy with azacitidine
* Prior therapy with lenalidomide
* Expected survival less than two months.
* Acute promyelocytic leukemia (APL)
* Central nervous system leukemia
* Serum biochemical values as follows

  1. Serum creatinine \>2.0 mg/dL (177 mmol/L)
  2. Serum aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transferase (ALT)/serum glutamate pyruvate transaminase (SGPT) \>3.0 x upper limit of normal (ULN)
  3. Serum total bilirubin \>1.5 mg/dL
* Prior allergic reaction to thalidomide
* Uncontrolled systemic infection

Primary outcomes:
measure: Response according to IWG criteria for MDS and AML
timeFrame: 25-44 weeks (after 6 cycles of azacitidine or azacitidine+lenalidomide)
Secondary outcomes:
measure: Cytogenetic response after 3 cycles using Fluorescence In Situ Hybridization(FISH)
timeFrame: 25-44 weeks
measure: Safety (number and types of adverse advents) in azacitidine vs azacitidine + lenalidomide groups
timeFrame: 25-44 weeks
measure: Azacitidine cycle interval between groups
timeFrame: 25-44 weeks
measure: Survival in azacitidine vs azacitidine + lenalidomide groups
timeFrame: Up to week 156
measure: Relapse in azacitidine vs azacitidine + lenalidomide groups
timeFrame: Up to week 156
measure: Analysis of a broad spectrum of molecular and cellular events which previously have been identified as related to MDS with del(5q).
timeFrame: 25-44 weeks
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Lars Möllgård
Study officials:
affiliation: Nordic MDS Group
name: Lars Möllgård, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: